Literature DB >> 12705635

Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells.

Rachael C Casey1, Theodore R Oegema, Keith M Skubitz, Stefan E Pambuccian, Suzanne M Grindle, Amy P N Skubitz.   

Abstract

We have previously shown that ovarian carcinoma cell adhesion to mesothelial cell monolayers and migration toward fibronectin, type IV collagen, and laminin is partially mediated by CD44, a proteoglycan known to affect the functional abilities of tumor cells. The purpose of this study was to determine the role of cell membrane glycosylation in the metastatic abilities of ovarian carcinoma cells. NIH:OVCAR5 cells were treated with glycosidases to remove carbohydrate moieties from molecules on the cells' surface. The ability of the treated cells to adhere to extracellular matrix components or mesothelial cell monolayers, migrate toward extracellular matrix proteins, and invade through Matrigel was assessed. We observed that the loss of different carbohydrate moieties resulted in altered ovarian carcinoma cell adhesion, migration, and/or invasion toward extracellular matrix components or mesothelial cell monolayers. Gene array analysis of NIH:OVCAR5 cells revealed the expression of several proteoglycans, including syndecan 4, decorin, and perlecan. In tissue samples obtained from patients, altered proteoglycan gene expression was observed in primary ovarian carcinoma tumors and secondary metastases, compared to normal ovaries. Taken together, these results suggest that ovarian carcinoma cell proteoglycans affect the cells' ability to adhere, migrate, and invade toward extracellular matrix components and mesothelial cell monolayers. Thus, the carbohydrate modifications of several proteoglycans may mediate the formation and spread of secondary tumor growth in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12705635     DOI: 10.1023/a:1022670501667

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

1.  Hyaluronate binding properties of versican.

Authors:  R G LeBaron; D R Zimmermann; E Ruoslahti
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

2.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.

Authors:  T Strobel; L Swanson; S A Cannistra
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

3.  Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis.

Authors:  M J Gardner; J B Catterall; L M Jones; G A Turner
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

Review 4.  Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.

Authors:  T C Hamilton; R C Young; R F Ozols
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

5.  Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization.

Authors:  Viji Shridhar; Ami Sen; Jeremy Chien; Julie Staub; Rajeswari Avula; Steve Kovats; John Lee; Jim Lillie; David I Smith
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

6.  Alterations in proteoglycan synthesis common to healing wounds and tumors.

Authors:  T K Yeo; L Brown; H F Dvorak
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

7.  CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration.

Authors:  L Y Bourguignon; H Zhu; L Shao; Y W Chen
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

8.  Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain.

Authors:  L C Ang; Y Zhang; L Cao; B L Yang; B Young; C Kiani; V Lee; K Allan; B B Yang
Journal:  J Neuropathol Exp Neurol       Date:  1999-06       Impact factor: 3.685

9.  Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.

Authors:  M V Dhodapkar; E Abe; A Theus; M Lacy; J K Langford; B Barlogie; R D Sanderson
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

10.  Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.

Authors:  R C Ridley; H Xiao; H Hata; J Woodliff; J Epstein; R D Sanderson
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

View more
  29 in total

1.  Migration dynamics of ovarian epithelial cells on micro-fabricated image-based models of normal and malignant stroma.

Authors:  Samuel Alkmin; Rebecca Brodziski; Haleigh Simon; Daniel Hinton; Randall H Goldsmith; Manish Patankar; Paul J Campagnola
Journal:  Acta Biomater       Date:  2019-09-27       Impact factor: 8.947

2.  MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.

Authors:  Rui-Qing Peng; Hai-Ying Wan; Hai-Fang Li; Min Liu; Xin Li; Hua Tang
Journal:  J Biol Chem       Date:  2012-03-07       Impact factor: 5.157

3.  Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.

Authors:  Miranda P Ween; Katja Hummitzsch; Raymond J Rodgers; Martin K Oehler; Carmela Ricciardelli
Journal:  Clin Exp Metastasis       Date:  2010-12-12       Impact factor: 5.150

4.  One-Year Plasma N-linked Glycome Intra-individual and Inter-individual Variability in the Chicken Model of Spontaneous Ovarian Adenocarcinoma.

Authors:  R Brent Dixon; Michael S Bereman; James N Petitte; Adam M Hawkridge; David C Muddiman
Journal:  Int J Mass Spectrom       Date:  2011-08-15       Impact factor: 1.986

Review 5.  Carbohydrate recognition by boronolectins, small molecules, and lectins.

Authors:  Shan Jin; Yunfeng Cheng; Suazette Reid; Minyong Li; Binghe Wang
Journal:  Med Res Rev       Date:  2010-03       Impact factor: 12.944

6.  Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

Authors:  John D Andersen; Kristin Lm Boylan; Ronald Jemmerson; Melissa A Geller; Benjamin Misemer; Katherine M Harrington; Starchild Weivoda; Bruce A Witthuhn; Peter Argenta; Rachel Isaksson Vogel; Amy Pn Skubitz
Journal:  J Ovarian Res       Date:  2010-09-10       Impact factor: 4.234

Review 7.  Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.

Authors:  Hilary A Kenny; Songuel Dogan; Marion Zillhardt; Anirban K Mitra; S Diane Yamada; Thomas Krausz; Ernst Lengyel
Journal:  Cancer Treat Res       Date:  2009

8.  Development of a robust and high throughput method for profiling N-linked glycans derived from plasma glycoproteins by NanoLC-FTICR mass spectrometry.

Authors:  Michael S Bereman; Douglas D Young; Alexander Deiters; David C Muddiman
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

9.  Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.

Authors:  Michael S Bereman; Taufika Islam Williams; David C Muddiman
Journal:  Anal Chem       Date:  2009-02-01       Impact factor: 6.986

10.  Differentiation of cancer cell origin and molecular subtype by plasma membrane N-glycan profiling.

Authors:  Serenus Hua; Mary Saunders; Lauren M Dimapasoc; Seung Hyup Jeong; Bum Jin Kim; Suhee Kim; Minkyung So; Kwang-Sik Lee; Jae Han Kim; Kit S Lam; Carlito B Lebrilla; Hyun Joo An
Journal:  J Proteome Res       Date:  2014-01-08       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.